Скачать или смотреть Wegovy or Zepbound? Which one is better? Results from SURMOUNT-5 trial.

The SURMOUNT-5 trial, a Phase 3b study, compared the efficacy of tirzepatide (Zepbound) and semaglutide (Wegovy) in adults with obesity or overweight and at least one weight-related comorbidity, excluding diabetes. Conducted over 72 weeks with 751 participants, the trial found that tirzepatide led to greater weight loss than semaglutide.

Key Findings
• Average Weight Loss: Participants on tirzepatide experienced an average weight reduction of 20.2% from baseline, compared to 13.7% for those on semaglutide.
• Significant Weight Reduction: A higher proportion of the tirzepatide group achieved substantial weight loss milestones:
• 31.6% lost at least 25% of their body weight, versus 16.1% in the semaglutide group.
• More participants on tirzepatide reached weight reductions of at least 10%, 15%, and 20% compared to those on semaglutide.
• Waist Circumference: Tirzepatide users saw an average waist reduction of 7.2 inches, while semaglutide users averaged a 5.1-inch reduction.

Safety Profile

Both medications exhibited similar safety profiles, with gastrointestinal issues like nausea and diarrhea being the most common side effects. These were generally mild to moderate and occurred primarily during dose escalation. Injection-site reactions were more frequent with tirzepatide, consistent with previous findings.

Mechanism of Action

Tirzepatide is a dual agonist, targeting both GIP and GLP-1 receptors, whereas semaglutide targets only the GLP-1 receptor. This dual mechanism may contribute to the enhanced weight loss observed with tirzepatide.

Clinical Implications

The SURMOUNT-5 trial provides strong evidence supporting tirzepatide as a more effective option for weight loss compared to semaglutide in individuals without diabetes. However, long-term studies are needed to assess the sustainability of weight loss and overall health outcomes.